Impact of statin therapy on coronary intervention for non-st elevation acute coronary syndrome with decreased low-density lipoprotein cholesterol

Journal of Cardiology

Volumn 49, Issue 3, 2007, Pages 115-123

  Hara, Hidehiko ^a   Nakamura, Masato ^b   Yokouchi, Itaru ^b   Kimura, Keiko ^c   Nemoto, Naohiko ^b   Ito, Shingo ^b   Ono, Tsuyoshi ^b   Shiba, Masanori ^b   Wada, Masamichi ^b   Tsuji, Takahiro ^b   Komatsu, Hirotaka ^b   Iijima, Raisuke ^b   Nakajima, Rintaro ^b   Yamamoto, Masaya ^b   Yamamoto, Masato ^b   Yoshitama, Takashi ^b   Takagi, Takuro ^b   Hara, Hisao ^b   Sugi, Kaoru ^b  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Angioplasty; Coronary artery disease; LDL; Lipid modifying agents; Lipoproteins; ST segments

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE; CREATINE KINASE MB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN T;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROL GROUP; CONTROLLED STUDY; DEATH; EVALUATION; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE INJURY; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; ST SEGMENT ELEVATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANGIOCARDIOGRAPHY; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; ELECTROCARDIOGRAPHY; MIDDLE AGED; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

EID: 34249710407     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Vun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engi J Med 1996; 335: 1001-1009.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N EngI J Med 1998; 339: 1349-1357.
4. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-1935.
5. Strandberg TE, Vanhanen H, Tikkanen MJ Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118-119.
6. Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF: Statins and C-reactive protein. Lancet 1999; 353: 1274.
7. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators: Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-235.
8. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S. Flaker GC, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-844.
9. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, La Placa FP, Patrono C: Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type ha hypercholesterolemia. Arterioscler Thromb Vase Biol 1995; 15: 247-251.
10. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D: Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-3177.
11. Dupuis J, TardifiC, Cernacek P, Theroux P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-3233.
12. Inhibition of the platelet glycoprotein fib/lila receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. NEnglJ Med 1998; 338: 1488- 1497.
13. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354: 708-715.
14. Herrmann J, Lerman A, Baunigart D, Volbracht L, Schulz R, von Birgelen C, Haude M, Heusch G, Erbel R: Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002; 106: 2180-2183.
15. Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P. Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P. Librera M, Bonizzoni E, Ricciardelli B: Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Eur Heart J 2004; 25: 1822-1828.
16. Okazaki 5, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H: Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
17. Kotani J, Nanto 5, Mintz GS, Kitakaze M, Ohara T, Morozumi T, Nagata 5, Hon M: Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation 2002; 106: 1672-1677.
18. Davignon J, Jacob RF, Mason RP: The antioxidant effects of statins. Coron Artery Dis 2004; 15: 25 1-258.
19. Patti G, Pasceni V, Nusca A, Di Sciascio G: Prevention of peniprocedural myocardial damage in patients undergoing percutaneous coronary intervention. Ital Heart J Suppl 2005; 6: 553-560 (in Italian with Eng abstr).
20. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol El, Ellis SG: Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107: 1750-1756.
21. Levitsky S: Protecting the myocardial cell during coronary revascularization: The William W. L. Glenn Lecture. Circulation 2006; 114(1 Suppl) : 1339-I 343.
22. Wang FW, Osman A, Otero J, Stouffer GA, Vaxman 5, Afzal A, Anzuini A, Uretsky BF: Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation 2003; 107: 2914- 2919.
23. Vijayalakshmi K, Whittaker VJ, Kunadian B, Graham J, Wright RA, Hall JA, Sutton AG, de B elder MA: Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 2006; 92: 1278-1284.
24. Li2m SY, Bae EH, Jeong MH, Kang DG, Lee YS, Kim KH, Lee SH, Yoon KH, Hong SN, Park HW, Hong YJ, Kim JH, Kim W, Ahn YK, Cho JG, Park JC, Kang JC: Effect of combined intracoronary adenosine and nicorandil on no- reflow phenomenon during percutaneous coronary intervention. Circ J 2004; 68: 928-932.
25. Pinto DS, Kirtane AJ, Ruocco NA, Deibele AJ, Shui A, Buros J, Murphy SA, Gibson CM: Administration of intracoronary eptifibatide during ST-elevation myocardial infarction. Am J Cardiol 2005; 96: 1494-1497.
26. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110: 674-678.
27. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-1718.
28. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, Vhite HD, Rouleau JL, Pedersen TR, Gardner LH, Mukhciec R, Ramsey KE, Palmisano J, Bilbeimer DW, Pfeffer MA, Califf RM, Braunwald E; A to Z Investigators: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 2004; 292: 1307-1316.